Evidence map›Paper›PMID 33668431›Full record

ArticleBiomolecules2021

Low Expression of miR-375 and miR-190b Differentiates Grade 3 Patients with Endometrial Cancer.

Miłosz Pietrus, Michał Seweryn, Przemysław Kapusta, Paweł Wołkow, Kazimierz Pityński, Gracjan Wątor

Abstract read
In one paragraph

Article in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Miłosz PietrusDepartment of Gynecology and Oncology, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Michał SewerynCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, 31-034 Krakow, Poland.
Przemysław KapustaCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, 31-034 Krakow, Poland.ORCID 0000-0003-4467-1175
Paweł WołkowCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, 31-034 Krakow, Poland.ORCID 0000-0002-9322-5545
Kazimierz PityńskiDepartment of Gynecology and Oncology, Jagiellonian University Medical College, 31-501 Krakow, Poland.
Gracjan WątorCenter for Medical Genomics OMICRON, Jagiellonian University Medical College, 31-034 Krakow, Poland.ORCID 0000-0003-0794-7275

Funding

Wydział Lekarski, Uniwersytet Jagielloński Collegium Medicum K/ZDS/004416
6 · The paper itself

Abstract

Endometrial cancer (EC) is treated according to the stage and prognostic risk factors. Most EC patients are in the early stages and they are treated surgically. However some of them, including those with high grade (grade 3) are in the intermediate and high intermediate prognostic risk groups and may require adjuvant therapy. The goal of the study was to find differences between grades based on an miRNA gene expression profile. Tumor samples from 24 patients with grade 1 (

Indexed as

AgedBiomarkers, TumorCohort StudiesEndometrial NeoplasmsFemaleGene Expression ProfilingGene OntologyHumansMicroRNAsMiddle AgedNeoplasm GradingReproducibility of ResultsRNA, MessengerBiomarkers, TumorMicroRNAsMIRN190b microRNA, humanMIRN375 microRNA, humanRNA, MessengerbiomarkersEC gradeendometrial cancermiRNANGS

Identifiers

PMID33668431
PMCPMC7918779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.